BioTelemetry (BEAT) Tops Q2 EPS by 3c
Get Alerts BEAT Hot Sheet
Join SI Premium – FREE
BioTelemetry (NASDAQ: BEAT) reported Q2 EPS of $0.20, $0.03 better than the analyst estimate of $0.17. Revenue for the quarter came in at $52.7 million versus the consensus estimate of $50.27 million.
GUIDANCE:
BioTelemetry sees Q3 2016 revenue of $210 million, versus the consensus of $202 million.
- adjusted EBITDA guidance to $44 to $46 million.
For earnings history and earnings-related data on BioTelemetry (BEAT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Teck Resources (TECK) Misses Q1 EPS by 15c; reaffirms FY guidance
- Sanofi (SNY) Tops Q1 EPS by 85c; reaffirms guidance
Create E-mail Alert Related Categories
Earnings, Guidance, Hot EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!